TW202415767A - 基於使用增強表現基因座之製備抗體的組成物及方法 - Google Patents

基於使用增強表現基因座之製備抗體的組成物及方法 Download PDF

Info

Publication number
TW202415767A
TW202415767A TW112130927A TW112130927A TW202415767A TW 202415767 A TW202415767 A TW 202415767A TW 112130927 A TW112130927 A TW 112130927A TW 112130927 A TW112130927 A TW 112130927A TW 202415767 A TW202415767 A TW 202415767A
Authority
TW
Taiwan
Prior art keywords
rrs
vector
nucleotide sequence
hcf
lcf
Prior art date
Application number
TW112130927A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 鮑比
達爾亞 布維克弗
剛 陳
詹姆斯 凡德
趙瑜
Original Assignee
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商再生元醫藥公司 filed Critical 美商再生元醫藥公司
Publication of TW202415767A publication Critical patent/TW202415767A/zh

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
TW112130927A 2016-04-20 2017-04-20 基於使用增強表現基因座之製備抗體的組成物及方法 TW202415767A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
US62/325,400 2016-04-20

Publications (1)

Publication Number Publication Date
TW202415767A true TW202415767A (zh) 2024-04-16

Family

ID=58701851

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112130927A TW202415767A (zh) 2016-04-20 2017-04-20 基於使用增強表現基因座之製備抗體的組成物及方法
TW106113298A TWI827531B (zh) 2016-04-20 2017-04-20 基於使用增強表現基因座之製備抗體的組成物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106113298A TWI827531B (zh) 2016-04-20 2017-04-20 基於使用增強表現基因座之製備抗體的組成物及方法

Country Status (15)

Country Link
US (2) US11512144B2 (OSRAM)
EP (1) EP3445781A1 (OSRAM)
JP (3) JP7096770B2 (OSRAM)
KR (1) KR102547738B1 (OSRAM)
CN (2) CN109195986B (OSRAM)
AR (1) AR109451A1 (OSRAM)
AU (2) AU2017253241B2 (OSRAM)
BR (1) BR112018071283A2 (OSRAM)
CA (1) CA3015389A1 (OSRAM)
EA (1) EA201892010A1 (OSRAM)
IL (2) IL314779A (OSRAM)
MX (2) MX2018012868A (OSRAM)
SG (2) SG10202010155YA (OSRAM)
TW (2) TW202415767A (OSRAM)
WO (1) WO2017184832A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018071283A2 (pt) * 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
CN113631711B (zh) * 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 核酸的靶向整合
WO2020204055A1 (ja) * 2019-04-02 2020-10-08 中外製薬株式会社 標的特異的な外来遺伝子の導入方法
CN114080454A (zh) 2019-06-26 2022-02-22 豪夫迈·罗氏有限公司 核酸的随机化构型靶向整合
TW202323529A (zh) 2021-10-18 2023-06-16 美商再生元醫藥公司 包括腺病毒相關病毒聚核苷酸的真核細胞
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
AU2022371200A1 (en) 2021-10-18 2024-05-02 Regeneron Pharmaceuticals, Inc. Controlled transcription of polynucleotides
KR20240117146A (ko) * 2021-12-22 2024-07-31 제넨테크, 인크. 다중 벡터 재조합효소 매개 카세트 교환
US20250361524A1 (en) * 2022-06-10 2025-11-27 Fujifilm Diosynth Biotechnologies Uk Limited Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, CHO cells, and cell pool
WO2025054526A1 (en) 2023-09-07 2025-03-13 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
DK1531666T3 (da) 2002-05-29 2014-01-13 Regeneron Pharma Inducerbart eukaryot-ekspressionssystem
JP2006512061A (ja) 2002-11-14 2006-04-13 ジェネンテック・インコーポレーテッド イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
JP2010514416A (ja) 2006-12-21 2010-05-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規な方法
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
ES2661074T3 (es) 2009-06-02 2018-03-27 Regeneron Pharmaceuticals, Inc. Células deficientes de fucosilación
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AU2010297011A1 (en) 2009-09-18 2012-04-12 Selexis S.A. Products and methods for enhanced transgene expression and processing
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015335921B2 (en) 2014-10-23 2020-06-25 Regeneron Pharmaceuticals, Inc. Novel CHO integration sites and uses thereof
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
BR112018071283A2 (pt) * 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.

Also Published As

Publication number Publication date
AR109451A1 (es) 2018-12-12
MX2018012868A (es) 2019-03-11
WO2017184832A1 (en) 2017-10-26
CN116515757A (zh) 2023-08-01
KR20180134893A (ko) 2018-12-19
AU2017253241B2 (en) 2024-07-04
IL262266B1 (en) 2024-09-01
SG10202010155YA (en) 2020-11-27
CN109195986A (zh) 2019-01-11
JP7096770B2 (ja) 2022-07-06
EA201892010A1 (ru) 2019-03-29
TW201803986A (zh) 2018-02-01
CN109195986B (zh) 2023-01-03
MX2025003852A (es) 2025-05-02
CA3015389A1 (en) 2017-10-26
SG11201807885PA (en) 2018-10-30
TWI827531B (zh) 2024-01-01
IL314779A (en) 2024-10-01
KR20230098361A (ko) 2023-07-03
JP2024023449A (ja) 2024-02-21
US20230130799A1 (en) 2023-04-27
JP2021164479A (ja) 2021-10-14
US11512144B2 (en) 2022-11-29
JP2019515666A (ja) 2019-06-13
US20190233544A1 (en) 2019-08-01
IL262266A (en) 2018-11-29
EP3445781A1 (en) 2019-02-27
AU2024220124A1 (en) 2024-10-17
KR102547738B1 (ko) 2023-06-26
BR112018071283A2 (pt) 2019-02-12
IL262266B2 (en) 2025-01-01
AU2017253241A1 (en) 2018-09-20
JP7781128B2 (ja) 2025-12-05

Similar Documents

Publication Publication Date Title
JP7789143B2 (ja) 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP7781128B2 (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2025188169A (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
KR102906454B1 (ko) 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию